Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635
ARWR Stock | USD 19.23 0.30 1.54% |
Slightly above 62% of Arrowhead Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Arrowhead Pharmaceuticals suggests that many traders are alarmed. Arrowhead Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Arrowhead Pharmaceuticals. Many technical investors use Arrowhead Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Arrowhead |
Arrowhead Pharmaceuticals, Inc. today announced that as an inducement to entering into employment with the Company, on October 11, 2024
Read at businesswire.com
![]() |
Arrowhead Pharmaceuticals Fundamental Analysis
We analyze Arrowhead Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Arrowhead Pharmaceuticals is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Arrowhead Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arrowhead Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Arrowhead Pharmaceuticals Related Equities
ASMB | Assembly Biosciences | 7.86 | ||||
AMLX | Amylyx Pharmaceuticals | 4.58 | ||||
PRQR | ProQR Therapeutics | 2.56 | ||||
WVE | Wave Life | 2.32 | ||||
TERN | Terns Pharmaceuticals | 1.35 | ||||
ANNX | Annexon | 0.78 | ||||
BPMC | Blueprint Medicines | 0.15 | ||||
INCY | Incyte | 0.13 | ||||
IONS | Ionis Pharmaceuticals | 0.28 | ||||
CTMX | CytomX Therapeutics | 1.45 | ||||
APLS | Apellis Pharmaceuticals | 2.12 | ||||
BMRN | Biomarin Pharmaceutical | 3.32 | ||||
DAWN | Day One | 16.50 |
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.